Home Blog Page 1722

Simcere’s IL-2 Mutant Fusion Protein SIM0278 Entered Phase II Clinical Trial Stage

By
Advertorial Desk
-

NANJING, China, Nov. 10, 2025 /PRNewswire/ — Simcere Pharmaceutical Group (2096.HK) announced that its regulatory T cells（Treg）-preferential IL-2 mutant Fc fusion protein (IL-2 mu-Fc), SIM0278, has officially entered a Phase II clinical study in China for the treatment of moderate-to-severe atopic dermatitis (AD). The first dose was achieved in Hangzhou First People’s Hospital.

This randomized, double-blind, placebo-controlled, multi-center Phase II study is aiming to evaluate the efficacy, safety, and pharmacokinetics of continuous subcutaneous administration of SIM0278 in participants with moderate-to-severe AD.

Atopic dermatitis is a chronic, recurrent, inflammatory skin disease characterized by symptoms such as dry skin, intense itching, and erythema, which significantly impact patients’ quality of life.  As a high medical need for the treatment of moderate to severe AD remains, there are opportunities to further optimise treatment options and technologies.

The critical role of Treg cells in peripheral immune tolerance is a major focus in current immunology research and was recently awarded the 2025 Nobel Prize. SIM0278 was developed on Simcere’s proprietary protein engineering platform. Its mechanism of action involves introducing mutations that reduce its affinity for effector T cells while maintaining high affinity for Tregs. This selectivity allows SIM0278 to activate Tregs specifically, helping to restore immune balance without affecting effector T cells or natural killer cells and shows potential for treating a variety of immune disorders. SIM0278 has demonstrated good tolerability, appropriate pharmacokinetic properties, and preliminary efficacy in the completed Phase I clinical study in China. It is expected to achieve sustained efficacy and become a best-in-class (BIC) product.

“We are excited about what SIM0278’s entry into Phase II means for AD patients and the long-term management of the disease. This partnership reinforces our commitment to pushing the boundaries of science and patient-centric innovation to deliver impactful solutions for unmet dermatological needs”, said Karl Ziegelbauer, Chief Scientific Officer at Almirall.

“The clinical progress of SIM0278 significantly strengthens Simcere’s leading position in the field of autoimmune diseases.” Said Dr Aik H Goh, MD , Chief Medical Officer of Simcere,” The initiation of Phase II clinical trials also marks a significant step forward in the project’s global clinical development plan. We look forward to working with our partner to bring this innovative drug to patients worldwide as soon as possible.”

In September 2022, Simcere signed an exclusive license agreement with Almirall, S.A., granting Almirall rights to develop and commercialize SIM0278 for all indications outside Greater China. The Phase I clinical study conducted by Almirall in the United States has been completed and a Phase II study on another skin condition will start in the coming months.

About Simcere

Simcere Pharmaceutical Group Limited（2096.HK） is a pharmaceutical company driven by innovation and focusing on four therapeutic areas including Neuroscience, Oncology, Autoimmune Diseases and Anti-infection. We proactively explore areas with significant unmet needs, and our mission is Providing Today’s Patients with Medicines of the Future. Our industry-leading capabilities and commitment to synergistic innovation have enabled various global strategic collaborations and we are seen as the partner of choice by industry peers, medical institutes, and research organizations across the globe.

Origin Agritech Strengthens Gene Editing Platform through Patent License Agreement with Shunfeng BioTech

By
Advertorial Desk
-

BEIJING, Nov. 10, 2025 /PRNewswire/ — Origin Agritech Ltd. (NASDAQ: SEED) (the “Company” or “Origin”), a leading Chinese agricultural technology company, today announced it has entered into a patent license agreement with Shandong Shunfeng Biotechnology Co., Ltd. (“Shunfeng BioTech”) for the Cas-SF01 gene editing tool. This collaboration grants Origin long-term access to fully IP-protected gene editing technologies, providing a solid foundation for the Company’s future research and development in trait gene editing. It also aims to accelerate the adoption of advanced gene editing technologies in corn breeding, marking a significant milestone in Origin’s efforts to develop high-density, high-yield, and adaptable corn varieties.

Advancing Breeding with Gene Editing Technology

The partnership builds upon Origin Agritech’s long-term collaboration with China Agricultural University. Together, they identified two key regulatory genes controlling corn leaf angle—ZmRAVL1 and ZmDWF4—whose functional studies have been published in Science and Nature, respectively.

Using Shunfeng BioTech’s proprietary Cas-SF01 gene editing platform, researchers successfully developed a series of edited corn induction lines, including ZmRAVL1-KO1 and ZmDWF4-KO1.

Origin’s acquisition of these edited corn induction lines addresses three strategic objectives:

  • Biosafety Compliance: Essential for completing evaluations required for agricultural gene editing
  • Direct Breeding Resources: Immediate application in future commercial hybrid development
  • Core Technology Foundation: Central to Origin’s “Smart Plant Architecture” corn breeding program

Technological Breakthrough: “Smart Plant Architecture” for Enhanced Yields

Functional validation demonstrates that ZmRAVL1-KO1 and ZmDWF4-KO1 effectively optimize corn leaf angle, creating a canopy structure characterized by compact upper leaves and open lower leaves. This “smart plant architecture” significantly improves field light interception and airflow, enabling higher planting density and greater yield potential.

“Enhancing corn yield through increased planting density has long been a global breeding goal, but traditional methods have limited progress,” said Mr. Bill Deng, VP and Head of R&D at Origin Agritech. “These edited induction lines enable precise and efficient improvement of plant architecture in elite germplasm. Combined with our proprietary Hi-3 induction line gene editing technology, we can complete variety upgrades rapidly while avoiding the genetic drag associated with conventional backcrossing.”

Commercialization Roadmap: Advancing Biosafety Evaluation

Origin Agritech has initiated the biosafety assessment process for the edited lines. Additionally, this license agreement provides a substantial advantage by facilitating biosafety approval for Origin’s current and future gene editing transformants utilizing Hi-3 one-step gene-editing method, for some of which the Company has already applied. The Company estimates obtaining final biosafety certification will require 1-2 years due to regulatory procedures and experimental timelines. Origin is committed to advancing this process and accelerating the commercialization of its gene editing innovations.

Mr. Deng continued, “The signing of this patent license agreement marks a significant step forward in Origin Agritech’s gene editing breeding strategy. By integrating world-class research resources with innovative biotechnological tools, we are building a modern breeding innovation system with proprietary intellectual property, contributing to China’s agricultural technology advancement and national food security.”

About Origin Agritech Limited

Origin Agritech Limited, founded in 1997 and headquartered at the Origin R&D Center in Songzhuang, Tongzhou, Beijing, is a leading agricultural technology company in China. In crop seed biotechnologies, Origin Agritech’s phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China’s Ministry of Agriculture. Over the years, Origin has established a robust biotechnology seed pipeline, including products with glyphosate tolerance and Bt (pest resistance) traits. For further information, please visit the Company’s website at www.originagritech.com. The Company also maintains an X account to update investors on company and industry developments, which can be found at https://x.com/origin_agritech.

Forward-Looking Statements

This communication contains “forward-looking statements” as defined in the federal securities laws, including Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements address expected future business and financial performance and financial condition and contain words like “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “will,” “would,” “target,” and similar expressions and variations. Forward-looking statements address matters that are uncertain. Forward-looking statements are not guarantees of future performance and are based on assumptions and expectations that may not be realized. They are based on management’s current expectations, assumptions, estimates, and projections regarding the Company and the industry in which it operates, but involve a number of risks and uncertainties, many of which are beyond the Company’s control. Some of the important factors that could cause the Company’s actual results to differ materially from those discussed in forward-looking statements are: failure to develop and market new products and optimally manage product life cycles; ability to respond to market acceptance, rules, regulations and policies affecting our products; failure to appropriately manage process safety and product stewardship issues; changes in laws and regulations or political conditions; global economic and capital markets conditions, such as inflation, interest and currency exchange rates; business or supply disruptions; natural disasters and weather events and patterns; ability to protect and enforce the Company’s intellectual property rights; and separation of underperforming or non-strategic assets or businesses. The Company undertakes no duty or obligation to publicly revise or update any forward-looking statements as a result of future developments, new information, or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure that such expectations will be correct. Actual results may differ materially from the anticipated results. You are urged to consider these factors carefully in evaluating the forward-looking statements contained herein. You are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements.

For more information, please contact:

Origin Agritech Limited Contact:
Kate Lang (Mandarin/English)
Director of Investor Relations
Phone: +86 186-1839-3368
Email: bing.lang@originseed.com.cn

Investor Relations Contact:
Matthew Abenante, IRC
President
Strategic Investor Relations, LLC
Tel: 347-947-2093
Email: matthew@strategic-ir.com 

LISCure Biosciences Initiates Global Phase 2 Trial of LB-P8 in Primary Sclerosing Cholangitis (PSC)

By
Advertorial Desk
-

SEOUL, South Korea, Nov. 10, 2025 /PRNewswire/ — LISCure Biosciences (“LISCure”), a clinical-stage biopharmaceutical company, announced the initiation of patient dosing in a global Phase 2 clinical trial of LB-P8, a novel therapeutic candidate for Primary Sclerosing Cholangitis (PSC), a rare and progressive liver disease with no approved treatments on November 5 (local time in the U.S.).

LB-P8: A First in Class Candidate Targeting the Gut-Liver axis

PSC is a cholestatic liver disease of unknown etiology, characterized by inflammation and fibrosis of the bile ducts, and currently has no approved treatment options worldwide.

LB-P8, LISCure’s investigational drug, acts by modulating the gut–liver axis to suppress inflammation and fibrosis. Preclinical and Phase 1 studies have demonstrated its safety and initial efficacy. Moreover, LB-P8 has shown therapeutic effects in inflammatory bowel disease (IBD), which coexists in approximately 80% of PSC patients, giving it a differentiated competitive edge over other drug candidates currently in development.

LB-P8 received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) in 2022 for the treatment of PSC and was granted Fast Track Designation in 2024. Recently, the Committee for Orphan Medicinal Products (COMP) under the European Medicines Agency (EMA) issued a positive opinion for LB-P8’s ODD, paving the way for its formal designation in Europe.

The ongoing Phase 2 trial (ClinicalTrials.gov Identifier: NCT06699121) will be conducted across 28 clinical sites in the United States and Europe.. The study aims to evaluate the safety, tolerability, and efficacy of LB-P8 in patients with PSC.

Hwasup Chin, CEO of LISCure, stated, “PSC represents an area of extremely high unmet medical need, as there are currently no approved therapeutic options. This milestone marks a meaningful step forward for both patients and healthcare professionals.” He added, “Together with our other core pipeline asset, the BBB shuttle platform ExoPN-101, we aim to continue advancing as a trusted global biotech company founded on solid scientific evidence and clinical data.”

Akeso Announces First Patient Dosed in Phase I Trial of Personalized mRNA Vaccine AK154 as Monotherapy or in Combination with Cadonilimab or Ivonescimab for Adjuvant Treatment of Pancreatic Cancer

By
Advertorial Desk
-

HONG KONG, Nov. 10, 2025 /PRNewswire/ — Akeso, Inc. (HKEX: 9926. HK) is pleased to announce that the first patient has been dosed in a Phase I clinical trial evaluating the personalized mRNA vaccine AK154. This trial is investigating AK154 both as a monotherapy and as a combination with the company’s first-in-class bispecific antibodies, cadonilimab (PD-1/CTLA-4) and ivonescimab (PD-1/VEGF), for the adjuvant treatment of pancreatic cancer following surgical resection.

AK154 is Akeso’s first mRNA-based therapeutic candidate to enter clinical development. This achievement marks a significant breakthrough for the company in the field of mRNA technology, following its established leadership in multi-specific antibodies, and entry into the clinic for its antibody-drug conjugates (ADCs).

AK154 is a personalized neoantigen vaccine developed by Akeso using its mRNA platform. It designs sequence-specific mRNA vaccines by sequencing tumor tissue and identifying immunogenic mutations with high affinity. This approach aims to overcome the “cold tumor” phenotype seen in pancreatic cancer.

AK154 shows a synergistic therapeutic effect with Akeso’s bispecific antibodies in enhancing anti-tumor immunity. Preclinical data demonstrated strong immunogenicity, potent anti-tumor activity, and a favorable safety profile. The combination of AK154 with cadonilimab or ivonescimab offers potentially promising new therapeutic options for pancreatic cancer patients.

Forward-Looking Statement of Akeso, Inc.
This announcement by Akeso, Inc. (9926.HK, “Akeso”) contains “forward-looking statements”. These statements reflect the current beliefs and expectations of Akeso’s management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso’s other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

About Akeso
Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world’s first or best-in-class innovative biological medicines. Founded in 2012, the company has created a unique integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the core, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode, and has gradually developed into a globally competitive biopharmaceutical company focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 24 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise.

For more information, please visit https://www.akesobio.com/en/about-us/corporate-profile/ and follow us on Linkedin.

GBA International Artificial Intelligence and Robotics Summit 2025 Opens Grandly “AI and Robotics Fest” Launches Alongside HKPC Drives AI for All and Embodied AI Adoption to Propel Hong Kong into a New Era of New Productive Forces

By
Advertorial Desk
-

HONG KONG SAR – Media OutReach Newswire – 10 November 2025 – The Hong Kong Productivity Council (HKPC) today officially opened the “GBA International Artificial Intelligence and Robotics Summit 2025,” themed “Empowering Resilient Industries through Embodied AI,” bringing together top experts from the Chinese Mainland, Switzerland, Germany, Italy, Japan, Korea and Hong Kong to explore the industrialisation of artificial intelligence (AI) and robotics. Professor Dong SUN, JP, Secretary for Innovation, Technology and Industry, officiated as the Guest of Honor. Running alongside the summit, the week-long “AI and Robotics Fest” showcase real-world AI applications in manufacturing, retail, logistics and urban management, advancing AI for All and empowering new productive forces.

Aligning with National Strategy on New Productive Forces and Local Policy Priorities Deepening Collaboration among Government, Industry, Academia, Research and Investment
The “15th Five-Year Plan” proposals emphasise leading the development of new productive forces, accelerating AI technological innovation, fully implementing the “AI+” initiative, and strengthening the integration of AI with industrial development and other sectors. The HKSAR Government has designated AI as a key industry and a core driver to nurture new productive forces and achieve new industrialisation in Hong Kong. HKPC will collaborate with industry partners to advance R&D in key AI technologies, promote widespread adoption, and strengthen talent development.

To align with national and HKSAR development directions and seize new opportunities in AI, this year’s Summit convenes leaders and experts from Government, Industry, Academia, Research and Investment to delve into topics including industrial innovation and tech synergy, AI application at scale, digital economy development, and smart city construction, facilitating in-depth discussion and knowledge sharing. The event not only brings the latest AI developments and cutting-edge case studies to the industry, but also promotes cross-sector collaboration to further enable AI across sectors—supporting Hong Kong’s journey toward new productive forces and high-quality development.

Professor Dong SUN, JP, Secretary for Innovation, Technology and Industry, said at the opening ceremony: “Our country’s support for Hong Kong to develop into an international innovation and technology centre is reaffirmed in the Recommendations of 15th Five-Year Plan just released. Hong Kong shall work closely with neighbouring cities to contribute to the high-quality development of the Greater Bay Area and the country. In this connection, AI and robotics remain top of our agenda. The Government adopts a multi-pronged approach in fostering the development of AI, from enhancing R&D (research and development) capabilities, cultivating and attracting talents, to building infrastructure and promoting AI-related industry applications.” He adds: “I hope events that pool together experts in the field – such as today’s Summit – will continue to inspire us to innovate, collaborate, and lead with purpose.”

From Proof of Concept to Commercial Scale Accelerating the Adoption of Humanoid Robots and Embodied Intelligence
The Humanoid Robotics Exhibition is open to the public, featuring advanced technologies including humanoid robots and quadruped robot dogs by Unitree Robotics and its Hong Kong agent POI Corporation; humanoid robots by Ubtech; humanoid and quadruped robots by Agibot and its Hong Kong agent Nokodar Autonomy; a flexible robotic arm by Flexiv; humanoid service robots by Keenon Robotics; and AI agent solutions by GPTBots.ai under Aurora, among others.

Mr Emil YU Chen-on, BBS, JP, Deputy Chairman of HKPC, said: “The global embodied AI market size is expected to exceed US$23 billion by 2030. China is poised to lead industry development and could capture nearly 30% of the market. The value of AI lies not in the technology itself, but in whether every enterprise and every employee can apply it with confidence. HKPC will continue to play four roles—promoter, connector, implementer, and gatekeeper. Our goal is to make AI not just understandable and affordable, but also deployable, truly advancing AI for All and the realisation of new productive forces.”

Four-day Theme Week Launches in Parallel Seamless Linkage of Tech Showcases, Guided Tours and Hands-on Experiences
Running alongside the AI Summit, the “AI and Robotics Fest” launches in parallel. Through hands-on experiences, guided tours and live scenario demonstrations, it addresses SMEs’ pain points in AI adoption—providing end-to-end support spanning governance, technology and talent—to help companies move from trials to scaled implementations.

According to the “AI Readiness in Workplace Survey 2025” released earlier by the HKPC Academy, nearly 90% of surveyed employees already use AI tools in daily work, yet over half of organisations have not established unified platforms or clear strategies, with talent and internal training cited as major challenges. This Summit and theme week aim to bridge these critical gaps and drive deeper AI adoption among enterprises, especially SMEs.

The theme week covers four key pillars, providing comprehensive support from standards and governance to scenario validation:

  1. Standards and Governance: HKPC officially launches the “AI Governance and Safety Assessment Service” and shares practical strategies on AI standards and cross-border compliance, helping enterprises build trustworthy and auditable AI frameworks.
  2. Technology and Solutions: On-site showcases feature multiple AI and humanoid robotics solutions across scenarios such as voice interaction, reception, data capture and logistics operations, with applications spanning manufacturing, services and education.
  3. Talent and Capability: Through guided tours and technical briefings, enterprise teams can rapidly grasp key AI application insights, supporting change management and internal capability-building during AI implementation.
  4. Live Scenarios and Validation: Realistic demonstrations in manufacturing, logistics, F&B and urban services allow enterprises to validate AI benefits with low pilot costs, shortening the distance from concept to deployment.

To support enterprises’ digital transformation and the social popularisation of AI, HKPC is advancing the “AI for All” initiative through three approaches—internal practice, skills training and technology platforms; training more than 22,000 people in two years; self-developing and widely deploying the internal AI tool “AIM”; and integrating over 250 ready-to-deploy applications into the “D-Biz Easy” platform to enable more SMEs to pilot and replicate AI solutions at low cost.

The programme runs through 13 November. The schedule is as follows:

Date/Time Activity highlights
10 November

09:30 – 17:00

GBA International Artificial Intelligence and Robotic Summit 2025

Under the theme of “Empowering Resilient Industries through Embodied AI”, the event brought together top experts from Chinese Mainland, Sweden, Germany, Italy, Japan and South Korea to discuss the future blueprint of smart technology.

11 November

14:30 – 17:30

“AI-Enabled Next-Generation Smart City” Symposium

An in-depth analysis of how AI is transforming public services, optimizing infrastructure operations, and driving sustainable urban living. The application of cutting-edge technologies such as generative AI models, AI robots, and AI safety technologies will be showcased, providing a fresh perspective for policy formulation and urban planning.

10 – 13 November

10:30 – 11:30 (Morning Session)

14:45 – 15:45 (Afternoon Session)

“AI and Robotics and Low-altitude Economy Tech Hall” guided tour

A glance at the latest global research and development achievements, showcasing the overall capabilities of cutting-edge AI and humanoid robots, integrating multi-modal perception, visual language understanding, and real-time reasoning, combined with full-body motion planning, balance control, and dexterous hand operation to achieve fine assembly, tool use, and two-hand collaboration.

13 November

14:30 – 17:00

AI Advanced Manufacturing Forum: International Cooperation Shapes the Future of Production

Closely following the theme of “Intelligent Manufacturing to Improve Quality and Co-shape Future Productivity”, it focuses on the latest advances and practical experience in AI-driven industrial applications, additive manufacturing, flexible high-throughput production, and independent industrial solutions.

Enterprises and the public are welcome to register today to join the “AI and Robotics Fest” activities from 10 to 13 November, and seize the AI-driven new era of industrial transformation. Registration link: https://campaigns.hkpc.org/en-hk/ai-robotics-fest.

To download hi-res photos, please click here.

Hashtag: #香港生產力促進局

The issuer is solely responsible for the content of this announcement.

About the Hong Kong Productivity Council

The Hong Kong Productivity Council (HKPC) is a multi-disciplinary organisation established by statute in 1967, to promote productivity through relentless drive of world-class advanced technologies and innovative service offerings to support Hong Kong enterprises. As a nationwide leader in innovative, market-driven research and development (R&D), specialising in leading technologies and all-rounded manufacturing services, HKPC promotes new industrialisation in Hong Kong and the Chinese Mainland and facilitates the development of new productive forces, leveraging innovation and technology (I&T), as well as bolstering Hong Kong to be an international innovation and technology centre and a smart city. The Council offers comprehensive innovative solutions for Hong Kong industries and enterprises to enhance competitiveness. To further support businesses in expanding into global markets, HKPC has established “The Cradle – Go Global Service Centre”, providing essential services to address businesses’ needs in product development, technology, manufacturing, and management, empowering enterprises to successfully go global. The Council partners and collaborates with local industries and enterprises and world-class R&D institutes to promote technology transfer, product innovation, and commercialisation through product innovation, technology transfer, creating value for industries. HKPC’s world-class R&D achievements have been widely recognised over the years, winning an array of local and overseas accolades.

In addition, HKPC offers SMEs and startups immediate and timely assistance in coping with the ever-changing business environment, and strengthens talent nurturing and Hong Kong’s competitiveness with FutureSkills training for enterprises and academia to enhance digital capabilities and STEM competencies.

For more information, please visit HKPC’s website: .

Bybit Adds Polkadot (DOT) to On-Chain Earn

By
Advertorial Desk
-

DUBAI, UAE, Nov. 10, 2025 /PRNewswire/ — Bybit, the world’s second-largest cryptocurrency exchange by trading volume, is thrilled to announce that its On-Chain Earn platform has recently added support for Polkadot (DOT) staking.

This new addition allows users to stake DOT directly on-chain through Bybit and earn stable returns while helping to secure the Polkadot network.

Polkadot, launched in 2020 by Ethereum co-founder Dr. Gavin Wood, is a multi-chain network designed to connect different blockchains. It enables the transfer of various types of data and assets between chains, improving interoperability and scalability. The network uses a shared security model where the main relay chain secures all connected parachains. DOT, Polkadot’s native token, is used for governance, staking, and bonding.

Bybit On-Chain Earn simplifies the staking process by managing the technical requirements on behalf of users. Participants can earn bonus annual percentage rates (APR) by maintaining a staking period of at least 24 hours. Earnings are distributed to users’ Funding Accounts daily at a fixed time. Once a redemption request is made, interest will no longer accrue.

To participate, users must complete Identity Verification Level 1 and comply with Bybit’s Terms of Service.

For more information, visit Bybit On-Chain Earn.

#Bybit / #CryptoArk

Bybit Adds Polkadot (DOT) to On-Chain Earn
Bybit Adds Polkadot (DOT) to On-Chain Earn

About Bybit

Bybit is the world’s second-largest cryptocurrency exchange by trading volume, serving a global community of over 70 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.

For more details about Bybit, please visit Bybit Press 

For media inquiries, please contact: media@bybit.com
For updates, please follow: Bybit’s Communities and Social Media

Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube

2025 Taiwan Design Expo “(((Changhua)))” Closes with Record-Breaking Scale and Attendance, Unveiling a New Changhua Transformed by Design

By
Advertorial Desk
-

TAIPEI, Nov. 10, 2025 /PRNewswire/ — Held annually across different locales and entering its 23rd edition in 2025, the Taiwan Design Expo is a pivotal fixture for the design industry. Organized by Taiwan Design Research Institute, this grand event not only attracts the attention of the younger generation and the design sector, but also serves as the definitive channel for visitors to immerse themselves in a host region’s unique context and traits. Beyond bolstering local cultural identity and pride, the expo forges a distinct city brand, cultivating regional allure and strategically integrating design thinking into urban governance to enhance the visibility of the host city.

The 2025 Taiwan Design Expo made its Changhua debut. Themed “(((Changhua)))”, the Expo epitomizes Changhua’s legacy as a strategic headquarters that coordinates and distributes all kinds of resources, projecting the region’s innovative capacity! The Expo spanned 3 zones, including Changhua City, Lukang Township, and Southern Changhua (Tianwei and Tianzhong), making it the most ambitious in terms of scope and venue count in the history of the event. The Changhua Area showcased the locality’s tremendous manufacturing expertise and design prowess; the Lukang Area celebrated its century-old humanistic history and spiritual tradition; and the Southern Changhua Area highlighted its thriving floral and horticulture sector, alongside its hidden industrial champions.

Beyond the exhibits, the event has driven sustained urban innovation across public space and industry revitalization. Examples include crafting a more human-centric urban environment and elevating the quality of public amenities; streamlining passenger flow and wayfinding system at Changhua Train Station and the Roundhouse; breathing new life into the Xiaoxi Commercial District via business advisory services and branding; and facilitating the upgrade and transformation of local industries. These efforts aim to broaden the impact when design thinking is deployed for urban governance.

The 2025 Taiwan Design Expo was a testament to Changhua’s enduring role as a headquarters for Taiwan’s logistics, commerce, and cultural exchange. Following its successful conclusion, the momentum of design remains to unlock boundless opportunities for the city’s future development!

Rhenus strengthens its Air Freight Gateways Network in Southeast Asia to support Global Trade

By
Advertorial Desk
-

  • The logistics solutions provider strengthens its setup in Southeast Asia as trade flows shift towards the region
  • Investment into a network of strategic gateways in Southeast Asia ensures that Rhenus is better positioned to support global customers across all logistics solutions

SINGAPORE – Media OutReach Newswire – 10 November 2025 – Leading global logistics provider Rhenus Group is steadily increasing its investments in Southeast Asia, as part of its ongoing plans to strengthen its presence across key trade corridors globally. The China+1 strategy has also influenced cargo flows in Southeast Asia, increasing cargo volumes and creating greater demand for more resilient, flexible and cost-effective logistics solutions.

Despite weaker external demand, elevated tariffs, and persistent policy uncertainty, Asia is expected to remain the biggest driver of global growth, contributing about 60%[1] in 2025 and 2026. Trade lanes between Asia and the world are seeing growth as well, as manufacturers prioritize Southeast Asia for their sourcing needs. According to IATA, air freight volumes, as of September 2025 saw the Europe/Asia corridor grew by 12.4%[2] YoY, reflecting a strategic shift in trade flows toward Southeast Asia as cities such as Bangkok and Kuala Lumpur increase in importance as key inbound and outbound hubs for European cargo. Trade between China and ASEAN totaled 3.67 trillion yuan[3], a YoY increase of 9.6%, compared to a 9.3% YoY decrease in terms of China’s trade with the United States.

“Southeast Asia is a focus growth area for Air Freight in Rhenus. The gateways are at the center of the company’s latest expansion plans, and go beyond delivering the global promise of reliable, customer-centric logistics solutions. They are designed with scalability in mind, and integrate the latest digital and sustainable logistics solutions, to give our global customers flexibility and efficiency,” said Chris Bode, Vice President Global Air Freight, Rhenus Air & Ocean.

From Southeast Asia to the World: Strategic Integration into global freight corridors

In 2025, Rhenus set up air freight gateways in key trade hubs in the region – Singapore & Thailand (Bangkok) and with the already existing Malaysia (Kuala Lumpur) – to optimize cargo flows across Southeast Asia and with global trade lanes. The strategic gateways strengthen the presence of Rhenus across key corridors, including (and not limited to):

  • Kuala Lumpur facilitates inbound cargo from Europe and outbound cargo to Oceania.
  • Singapore handles inbound cargo from Asia or Oceania, and outbound cargo to the Americas.
  • Bangkok manages outbound cargo to Europe and serves as a multi-modal hub to enhance Intra-Asia trade capabilities through regional air freight and cross-border trucking.

The fully operational gateways, with the flexibility for phased expansions, offer a full suite of solutions, door-to-door services, customs clearance, cargo consolidation and value-added air freight services. Technology-enabled capabilities, such as smart logistics platforms, real-time tracking and digital documentation to streamline operations, power the gateways. Sustainable logistics initiatives, such as electric vehicles for pre and on-carriage, optimized routing and low-emission transport options, will also be embedded across all three gateways.

Joachim Hanssen, CEO APAC, Rhenus Air & Ocean, said, “With recent global developments, including the China +1 strategy, more businesses are set to include the Southeast Asian region as an increasingly important piece of their global logistics plans. Rhenus has been and remains committed to support our customers in these fast-growing markets. We are confident that our strategic plans to grow our capabilities in this region, by enhancing resilience and operational agility, will position us as a preferred partner to meet evolving regional and global trade needs.”

Looking ahead, Rhenus will continue to identify strategic investment opportunities in Southeast Asia and the overall APAC region, as part of its commitment to support and facilitate its customers globally.

[1]https://www.imf.org/en/Blogs/Articles/2025/10/16/asias-economic-growth-is-weathering-tariffs-and-uncertainty

[3]https://english.www.gov.cn/archive/statistics/202507/14/content_WS6874fdcfc6d0868f4e8f4236.html

Hashtag: #Rhenus

The issuer is solely responsible for the content of this announcement.

About Rhenus

The Rhenus Group is one of the leading logistics specialists with global business operations and annual turnover amounting to EUR 8.2 billion. 41,000 employees work at 1,330 business sites in more than 70 countries and develop innovative solutions along the complete supply chain. Whether providing transport, warehousing, customs clearance or value-added services, the family-owned business pools its operations in various business units where the needs of customers are the major focus at all times.

1...1,7211,7221,723...6,323Page 1,722 of 6,323